ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Budesonide

Also written as “budesonide”, “budesonide/formoterol” and “BGF MDI 320/14.4/9.6 μg”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Eosinophilic Esophagitis · Colitis, Ulcerative · Glomerulonephritis, IGA, led by 35 companies.

Drug pageBudesonide: every studyMany companies study it; this page follows only the 163 they lead. All 307 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 27, 2005163 company-led studies, 8 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only692 open or runningphase 4since Sep 27, 2005Sep 13, 2005May 31, 2027phase 4 · NCT07073950
Dr. Falk Pharma171 open or runningphase 3since Mar 7, 2006Mar 7, 2006Dec 2026phase 3 · NCT06596252
Bausch Health Companiesits history only91 open or runningphase 4since Mar 17, 2020May 14, 2008Dec 2026phase 4 · NCT04314375
Takedaits history only60 open or runningphase 3since Nov 4, 2015Sep 29, 2008none ahead
AbbVieits history only50 open or runningphase 3since Dec 5, 2007Oct 30, 2007none ahead
Calliditas Therapeutics ABits history only51 open or runningphase 4since Nov 20, 2024Oct 5, 2008Mar 2027phase 4 · NCT06712407
Intech Biopharmits history only50 open or runningphase 2since Jun 11, 2014Jun 11, 2014none ahead
Chenpon Pharmaceuticalits history only30 open or runningphase 3since Aug 24, 2026Aug 24, 2026none ahead
Eurofarma Laboratoriosits history only30 open or runningphase 3since Oct 23, 2009Oct 23, 2009none ahead
Novartisits history only30 open or runningphase 4since Feb 15, 2013Feb 15, 2013none ahead

Also a collaborator on its studies: Parexel, Fortrea, Takeda Development Center Americas, Iqvia Pty, Premier, Hikma Pharmaceuticals, Cosmo Technologies, MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan, Q-Pharm Pty and Kyowa Kirin.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Dr. Falk Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Mar 7, 2006.

  1. Sep 3, 20082 phase 3 studiesNCT00747110, NCT00746486
  2. Jan 22, 2009Phase 2 study in Radiation ProctitisNCT00828230 · 17 enrolled · Germany
  3. Feb 5, 2009Phase 3 study in Hepatitis, AutoimmuneNCT00838214 · 208 enrolled · Germany
  4. Apr 22, 2009Phase 3 study in Oral Chronic Graft vs Host DiseaseNCT00887263 · 186 enrolled · Germany, Israel
  5. Mar 12, 2010Phase 3 study in Crohn DiseaseNCT01086553 · 471 enrolled · Germany
  6. Sep 23, 2010Phase 3 study in Colitis, LymphocyticNCT01209208 · 57 enrolled · Germany
  7. Jan 14, 2011Phase 3 study in Colitis, CollagenousNCT01278082 · 92 enrolled · Germany, Sweden
  8. Oct 9, 2013Phase 2 study in ProctitisNCT01966783 · 320 enrolled · Germany
  9. May 14, 2014Phase 3 study in Incomplete Microscopic ColitisNCT02142634 · 44 enrolled · Germany, Sweden
  10. Oct 29, 2014Phase 2 study in Eosinophilic EsophagitisNCT02280616 · 76 enrolled · Germany
  11. Apr 30, 2015Phase 3 study in Eosinophilic EsophagitisNCT02434029 · 88 enrolled · Germany
  12. Jul 7, 2015Phase 3 study in Eosinophilic EsophagitisNCT02493335 · 204 enrolled · Germany
  13. Sep 14, 2015Phase 2 study in Colitis, UlcerativeNCT02550418 · 60 enrolled · Germany
  14. Sep 11, 2024Phase 3 study in Eosinophilic EsophagitisNCT06596252 · 308 enrolled · United States, Spain

Ahead

  1. Dec 2026Primary completion: phase 3 study in Eosinophilic EsophagitisNCT06596252

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
DexamethasoneruleAbbViephase 4174
fluticasone furoateruleGlaxoSmithKlinephase 497
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
betamethasone dipropionateruleLEO Pharmaphase 427
MethylprednisolonerulePfizerphase 423
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
BetamethasoneruleLEO Pharmaphase 49
Triamcinoloneruleresearch-insight-llcphase 45
relacorilantruleCorcept Therapeuticsphase 322
Triamcinolone Acetonideruleclearside-biomedical-incphase 320

Studies

All 17 Dr. Falk Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06596252Eosinophilic Esophagitis · United States, Spain3Active, not recruitingDec 2026308
NCT02550418Colitis, Ulcerative · Germany2CompletedMar 201760
NCT02493335Eosinophilic Esophagitis · Germany3CompletedNov 28, 2018204
NCT02434029Eosinophilic Esophagitis · Germany3CompletedAug 4, 201688
NCT02280616Eosinophilic Esophagitis · Germany2CompletedApr 201376
NCT02142634Incomplete Microscopic Colitis · Germany, Sweden3CompletedFeb 202044
NCT01966783Proctitis · Germany2CompletedAug 2015320
NCT01278082Colitis, Collagenous · Germany, Sweden3CompletedMar 201392
NCT01209208Colitis, Lymphocytic · Germany3CompletedJun 201757
NCT01086553Crohn Disease · Germany3CompletedMay 2012471
NCT00887263Oral Chronic Graft vs Host Disease · Germany, Israel3CompletedOct 2015186
NCT00838214Hepatitis, Autoimmune · Germany3CompletedDec 2008208
NCT00828230Radiation Proctitis · Germany2TerminatedAug 201117
NCT00747110Colitis, Ulcerative · Germany3CompletedAug 2008343
NCT00746486Liver Cirrhosis, Biliary · France, Germany3TerminatedOct 201962
NCT00450086Colitis, Collagenous · Germany3CompletedJun 201192
NCT00300118Crohn Disease · Germany3CompletedMay 2008311

How it is read

Names in the registry

  • “Budesonide”, 45 entries
  • “budesonide”, 18 entries
  • “budesonide/formoterol”, 10 entries
  • “BGF MDI 320/14.4/9.6 μg”, 6 entries
  • “BFF MDI 320/9.6 μg”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.